A federal jury on Feb. 22 convicts four executives of Cincinnati-based Berkeley Premium Nutraceuticals, marketer of Enzyte "male enhancement" supplements, of conspiracy and fraud on criminal charges of money laundering, fraud and obstruction of justice. A federal grand jury indicted the firm, Berkeley's President Steve Warshak, his mother and five additional defendants and co-conspirators on a total of 112 criminal charges in September 2006 (1"The Tan Sheet" Sept. 25, 2006, In Brief). The trial jury in the U.S. District Court for Southern Ohio also found on Feb. 26 that Berkeley, Warshak, his mother and TCI Media, another company owned by Warshak, should forfeit to the U.S. more than $33 million in assets that were proceeds of the crimes. In addition, the jury convicted Paul J. Kellogg and Steven P. Pugh. Berkeley also settled with six states in March 2006 for $2.5 million (2"The Tan Sheet" March 6, 2006, p. 8)...

The final opinion of ECHA’s Socio-Economic Analysis Committee, published on 1 March, is largely unchanged from its July 2020 draft opinion with regard to microplastic in cosmetic products. That means industry may have to convince EU member state authorities that the restriction proposal has a serious proportionality problem.

Representatives from cardiac monitoring device manufacturers and professional societies are working together to persuade Medicare carrier Novitas to reconsider its payment rates for extended cardiac monitoring. See what Michael Coyle, iRhythm’s CEO, said about it here.